Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Overland ADCT Starts China Trial of ADC for B-cell Lymphoma

publication date: Jul 11, 2022

Overland ADCT BioPharma, a JV created by Overland Pharma and Lausanne’s ADC Therapeutics, dosed the first patient in a China trial of Zynonta® as a therapy for transfer-ineligible patients with diffuse large B-cell lymphoma (DLBCL). Overland Pharma, backed by Beijing’s Hillhouse Capital, is a Boston-Shanghai pharma that uses partnerships to bring novel medicines to Asia. Three months ago, Zynonta was the first CD19 ADC approved in the US. The JV will join a global Zynonta Phase III trial as a second-line therapy in the US and China for transplant-ineligible patients. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital